Cellular rejuvenation reaches a human trial
First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients. For the better part of a decade, partial reprogramming has been longevity biotech’s most seductive what-if. Reverse the epigenetic drift that builds up with age, stop well sho
<p>First-in-human ER-100 data support dose escalation, with early visual-field signals in two of three glaucoma patients. For the better part of a decade, partial reprogramming has been longevity biotech’s most seductive what-if. Reverse the epigenetic drift that builds up with age, stop well sho</p>